Abstract:Background Intra-articular therapy has a long history in treating inflamed arthritis, especially mono-oligoarthritis. Many different compounds are used. Since 19709s, a number of short-term studies have demonstrated Intra-articular administration of MTX can inhibit toxic oxygen metabolite release, lymphocyte proliferation and production of tumour necrosis factor alpha (TNF-a), interleukin (IL)-6 and IL-8 on the synovial membrane[1]. The therapy of MTX i.a. was gradually used in JIA, RA, PsA and knee synovitis with possibly favorable results and rare negative side effects. In the MTX/GS injection, we use not only MTX but also a large volume of 10% glucose solution (GS) to release adhesive tissue by fluid tension and ease joint pain which already was shown benefit to improve metabolism environment in joint cavity. In order to provide clinicians with the highest level of evidence and evaluate the efficacy and safety of this intra-articular therapy, we conducted a 24-week trial in 90 ankylosing spondylitis (AS) patients with single knee synovitis from Nov. 2006 to Mar. 2012. Objectives To evaluate efficacy and safety of intra-articular therapy with methotraxate in large volume of 10% glucose injection in ankylosing spondylitis (AS) patients with knee synovitis. Methods AS patients with knee synovitis (n=90) were randomly divided into three groups. 50 patients in MTX/GS group were treated with intra-articular injection of MTX (15 mg) in 10% Glucose solution (20ml) every week for 8 times, while 20 patients in GS group with intra-articular injection of 10% Glucose solution (20ml) every week for 8 times, and 20 patients in control group without injection. All the patients received ibuprofen sustained release tablets 0.3 twice dialy and sulfasalazine 1g twice daily. Same dose of MTX (15 mg once weekly) were given orally to the patients in GS group and control group. At the beginning of the treatment and after 4, 8 and 24 weeks, all the patients underwent a clinical evaluation, measuring maximal angle of knee movement, knee pain with visual analogscale (VAS), swelling with joint circumference, global assessment (ASA20, PGA, BASMI, BASDAI, BASFI). Erythrocyte edimentation rate (ESR) and C-reactive protein were tested. Results Joint pain, range of joint movement, circumference of swollen joint, ESR, CRP, patient9s global assessment (PGA) in MTX/GS group are significantly improved after 4 weeks of treatment in comparison with baseline and other groups at same time point (P<0.01-0.05). Adverse reactions in MTX/GS group were less than other groups. No serious adverse events occurred in all the patients. Axial symptoms were no significant difference in three groups. At all time point, MTX/GS group had better improvement in ASA20, BASMI, BASFI than other groups without statistic difference. No serious adverse events occurred in all the patients. Adverse reactions in MTX/GS group were less than other groups. Conclusions Compared to MTX orally taken, the repeated intra-articular injections of MTX glucose solution can suppress knee synovitis earlier and safely in AS patients. The intra-articular therapy of MTX/GS is another option in refractory monoarthritis. References Iagnocco A, Cerioni A, Coari G et al. Intra-articular methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis: a clinical and sonographic study. DClin Rheumatol. 2006 Mar;25(2):159-63. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.2631

Methotrexate for hip involvement of ankylosing spondylitis:a clinical study

Methotrexate versus sulfasalazine in the treatment of ankylosing spondylitis

Long-term efficacy of sulfasalazine,methotrexate and sulfasalazine combined with methotrexate in treatment of ankylosing spondylitis:a clinical study

Efficacy of Biological Agents Combined with Methotrexate and Sulfasalazine for Ankylosing Spondylitis with Hip Joint Involvement

Efficacy and Safety of Intra-Articular Therapy with Methotrexate in Large Volume of Glucose Injection on Knee Synovitis in Patients with Ankylosing Spondylitis

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

Clinical Observation on the Treatment of Juvenile Idiopathic Arthritis with Methotrexate Combining Total Glucosides of Peony

SAT0364 Efficacy and Safety of Intra-Articular Therapy with Methotraxate in Large Glucose Injection Volume on Knee Synovitis in Patients with Ankylosing Spondylitis

[Radiological Progression and Life Quality Analysis in Ankylosing Spondylitis Patients Using Etanercept/methotrexate Combination Therapy].

Treatment of Active Ankylosing Spondylitis with Leflunomide and Methotrexate : a Prospective Controlled Clinical Trial

Short Research on the Efficacy and Safety of Methotrexate Combined with the TNF-α Receptor Fusion Protein Etanercept in Patients with Severe Undifferentiated Spondyloarthropathy

The clinical and MRI effect of TNF-α inhibitor in spondyloarthritis patients with hip involvement: a real-world prospective clinical study

The Clinical and MRI Effect of TNF- Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study

Efficacy and Safety of Methotrexate Combined Iguratimod in Treatment of Active Rheumatoid Arthritis

Meta-analysis of the effectiveness and safety of sulfasalazine in the treatment of ankylosing spondylitis

Methotrexate Combined with Conventional DMARDs or Biological Agents for Rheumatoid Arthritis

Medium-term follow-up outcomes of total hip arthroplasty for patients with ankylosing spondylitis]

Clinical Efficacy of Etanercept for Treating Ankylosing Spondylitis in 60 Cases

Methotrexate for chronic non-necrotizing anterior scleritis in Chinese patients

Safety and Efficacy of Etanercept-Methotrexate Combination Therapy in Patients with Rhupus: an Observational Study of Non-glucocorticoid Treatment for Rheumatic Diseases

Clinical Observation on Total Glucosides of Paeony Combined with Sulfasalazine in Treatment of Ankylosing Spondylitis